MetaADEDB 2.0 @ LMMD
Nicardipine
(AIKVCUNQWYTVTO-UHFFFAOYSA-N)
Structure
SMILES
COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCN(Cc1ccccc1)C)C.Cl
Molecular Formula:
C26H30ClN3O6
Molecular Weight:
515.986
Log P:
5.3318
Hydrogen Bond Acceptor:
6
Hydrogen Bond Donor:
2
TPSA:
113.69
CAS Number(s):
54527-84-3; 69441-18-5
Synonym(s)
1.
Nicardipine
2.
Antagonil
3.
Cardene
4.
Cardene I.V.
5.
Cardene SR
6.
Dagan
7.
Flusemide
8.
Lecibral
9.
Lincil
10.
Loxen
11.
Lucenfal
12.
Nicardipine Hydrochloride
13.
Nicardipine LA
14.
Nicardipino Ratiopharm
15.
Nicardipino Seid
16.
Perdipine
17.
Ridene
18.
Vasonase
19.
Y-93
20.
Hydrochloride, Nicardipine
21.
LA, Nicardipine
22.
Y 93
23.
Y93
External Link(s)
MeSHD009529
PubChem Compound41114
49853450
ChEBI7551
CHEMBLCHEMBL1200326
CHEMBL3199626
KEGGdr:D00617
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug exposure during pregnancyFAERS: 35US FAERS
2ExtravasationFAERS: 14US FAERS
3HypotensionFAERS: 11US FAERS
4HypoxiaFAERS: 11US FAERS
5Patent ductus arteriosusFAERS: 11US FAERS
6Respiratory distressFAERS: 7US FAERS
7Cerebral InfarctionFAERS: 6US FAERS
8PalpitationsFAERS: 5US FAERS
9Left ventricle outflow tract obstructionFAERS: 4US FAERS
10PneumoniaFAERS: 4US FAERS
11Skin UlcerFAERS: 4US FAERS
12VasculitisFAERS: 4US FAERS
13ChillsFAERS: 3US FAERS
14PhlebitisFAERS: 3US FAERS
15PruritusFAERS: 3US FAERS
16Blood potassium decreasedFAERS: 2US FAERS
17BradycardiaFAERS: 2US FAERS
18CellulitisFAERS: 2US FAERS
19Cerebrovascular accidentFAERS: 2US FAERS
20Complications of maternal exposure to therapeutic drugsFAERS: 2US FAERS
21Depressed Level of ConsciousnessFAERS: 2US FAERS
22DizzinessFAERS: 2US FAERS
23Drug ineffectiveFAERS: 2US FAERS
24Flank PainFAERS: 2US FAERS
25Infusion Site ExtravasationFAERS: 2US FAERS
26Infusion site reactionFAERS: 2US FAERS
27Injection site abscessFAERS: 2US FAERS
28Leukocytoclastic vasculitisFAERS: 2US FAERS
29LymphangitisFAERS: 2US FAERS
30Myocardial InfarctionFAERS: 2US FAERS
31Neonatal hypotensionFAERS: 2US FAERS
32Off label use of deviceFAERS: 2US FAERS
33OverdoseFAERS: 2US FAERS
34Pericardial effusionFAERS: 2US FAERS
35PeritonitisFAERS: 2US FAERS
36Pharmaceutical product complaintFAERS: 2US FAERS
37Product packaging confusionFAERS: 2US FAERS
38Product substitution issueFAERS: 2US FAERS
39PurpuraFAERS: 2
Canada Vigilance: 1		Canada Vigilance
US FAERS
40Respiratory FailureFAERS: 2US FAERS
41RestlessnessFAERS: 2US FAERS
42TachycardiaFAERS: 2US FAERS
43Troponin increasedFAERS: 2US FAERS
44Ventricular hyperkinesiaFAERS: 2US FAERS
45AngioedemaFAERS: 1US FAERS
46AnorexiaFAERS: 1US FAERS
47Atrial FibrillationFAERS: 1US FAERS
48Back PainFAERS: 1US FAERS
49Brain natriuretic peptide increasedFAERS: 1US FAERS
50Burning sensationFAERS: 1US FAERS
51ChorioamnionitisFAERS: 1US FAERS
52Completed SuicideFAERS: 1US FAERS
53Disease recurrenceFAERS: 1US FAERS
54Drug administration errorFAERS: 1US FAERS
55Drug dispensing errorFAERS: 1US FAERS
56Drug label confusionFAERS: 1US FAERS
57EczemaFAERS: 1US FAERS
58Electrocardiogram repolarisation abnormalityFAERS: 1US FAERS
59FatigueFAERS: 1US FAERS
60Fluid overloadFAERS: 1US FAERS
61Gaze palsyFAERS: 1US FAERS
62HeadacheFAERS: 1US FAERS
63HemiplegiaFAERS: 1US FAERS
64HepatitisFAERS: 1US FAERS
65Hypertensive EncephalopathyFAERS: 1US FAERS
66IleusFAERS: 1US FAERS
67Incorrect dose administeredFAERS: 1US FAERS
68Incorrect drug administration rateFAERS: 1US FAERS
69InfectionFAERS: 1US FAERS
70Infusion site erythemaFAERS: 1US FAERS
71Infusion site phlebitisFAERS: 1US FAERS
72Infusion site ulcerFAERS: 1US FAERS
73Injection site extravasationFAERS: 1US FAERS
74Injection site phlebitisFAERS: 1US FAERS
75Intestinal gangreneFAERS: 1US FAERS
76Lack of infusion site rotationFAERS: 1US FAERS
77MalaiseFAERS: 1US FAERS
78Maternal exposure during pregnancyFAERS: 1US FAERS
79Maternal exposure timing unspecifiedFAERS: 1US FAERS
80Medication ErrorFAERS: 1US FAERS
81NecrosisFAERS: 1US FAERS
82Neonatal disorderFAERS: 1US FAERS
83Packaging design issueFAERS: 1US FAERS
84PainFAERS: 1US FAERS
85Platelet aggregation inhibitionFAERS: 1US FAERS
86Post procedural complicationFAERS: 1US FAERS
87Pre-EclampsiaFAERS: 1US FAERS
88Procedural hypertensionFAERS: 1US FAERS
89Product label confusionFAERS: 1US FAERS
90Product packaging issueFAERS: 1US FAERS
91Product quality issueFAERS: 1US FAERS
92Pulmonary EmbolismFAERS: 1US FAERS
93Pulmonary FibrosisFAERS: 1US FAERS
94Soft tissue necrosisFAERS: 1US FAERS
95TachyarrhythmiaFAERS: 1US FAERS
96VasospasmFAERS: 1US FAERS
97Wrong product procuredFAERS: 1US FAERS
98Wrong technique in drug usage processFAERS: 1US FAERS
99nervous system disorderFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120295

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.